Investment, Funding & Disinvestments

Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.

The transaction, which remains subject to customary regulatory approvals, marks the beginning of what both firms describe as Syntegon’s next major growth phase.

Construction crews have already broken ground on the expansion project, which Axplora expects to complete by February 2027.

The acquisition involves Novartis purchasing Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics that holds the rights to SNV4818 and related research programs.

The new production hub will be located in the Lin-gang Special Area of the Shanghai Free Trade Zone, where it will supply autologous CAR-T therapies to China and other Asian markets.

TPI’s new East Coast plant will complement its existing facility in Everett, Washington, where the company is also expanding capacity.

Imperative Care reports that medical professionals have used its products commercially in more than 78,000 procedures, demonstrating significant market adoption and clinical trust.

This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.

The merger is set to complete within the next quarter, pending final regulatory and statutory approvals from the National Company Law Tribunal (NCLT).

LYOCONTRACT has partnered with Syntegon, a leading equipment supplier, to install a complete filling and lyophilization line at the new facility.